1 Oct
2021

Biopharma IP licensors are getting more money - and earlier - for their innovations

Though pharma M&A is stagnant, innovators are finding other avenues to monetise their IP, receiving larger upfront payments for partnership agreements than ever before

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth